Trial Site Detail

 

Drug:
CB-839
Trial:
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
Conditions: Solid Tumors
Trial Status:
Recruiting

 

Dana Farber Cancer Institute

450 Brookline Ave     
Boston , MA 02215-5450
USA

 

Principal Investigator:
Geoffrey I. Shapiro
Contact:
Site Public Contact: 877-442-3324
Activation Status of this Site:
Active
Notes about this Site:
Dana Farber Cancer Institute Website:
http://www.dana-farber.org/Research/Clinical-Trials.aspx

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.